Abstract
A total of 28 patients were treated with mitoxantrone, vinorelbine and prednisone every 3 weeks. In all, 11 patients (46%) had a significant prostate-specific antigen decline for a median duration of 11.4 months. Eight patients (33%) achieved a partial response on pain, while seven (29%) obtained a stabilisation of the symptom. Median duration of the response was 9.5 months. A confirmed partial response was obtained in three out of seven patients who had bidimensionally measurable disease. Toxicity was manageable. Our study provides further support to the concept of combined antimicrotubule therapy for metastatic harmonoresistant prostate cancer, promoting the exploration of new regimens containing antimicrotubule agents in addition to mitoxantrone-prednisone.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Oral
-
Aged
-
Antineoplastic Agents, Hormonal / pharmacology
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Drug Administration Schedule
-
Drug Resistance, Neoplasm
-
Humans
-
Infusions, Intravenous
-
Male
-
Middle Aged
-
Mitoxantrone / administration & dosage
-
Mitoxantrone / therapeutic use
-
Prednisone / administration & dosage
-
Prednisone / therapeutic use
-
Prostatic Neoplasms / drug therapy*
-
Prostatic Neoplasms / pathology
-
Treatment Outcome
-
Vinblastine / administration & dosage
-
Vinblastine / analogs & derivatives*
-
Vinblastine / therapeutic use
-
Vinorelbine
Substances
-
Antineoplastic Agents, Hormonal
-
Vinblastine
-
Mitoxantrone
-
Vinorelbine
-
Prednisone